Compare Suncor Energy Inc. (SU) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Suncor Energy Inc. vs TransMedics Group Inc — how do they compare? Suncor Energy Inc. trades at $72.23 (market cap $82.76B), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: Suncor Energy Inc. is far larger — about 30.2× TransMedics Group Inc's market cap, and Suncor Energy Inc. pays a 2.39% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Suncor Energy Inc. for 57 Days and TransMedics Group Inc for 24 Days on average.
| SU | TMDX | |
|---|---|---|
Market Cap | $82.76B | $2.74B |
Volume | 3,832,959 | 949,331 |
Sector | Energy | Health |
52-Week High | $72.23 | $150.42 |
52-Week Low | $38.17 | $61.99 |
Typical Hold Time | 57 Days | 24 Days |
Enterprise Value | $89.29B | $3.13B |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Suncor Energy (SU) trades at $70.91, up 4.07% today and near its 52-week high. The stock exhibits a bullish technical trend with strong moving average support. Fundamentally, the company reported a net income margin of 14.7% for 2025 and a robust ROE of 19.25%. Recent news highlights asset divestitures and a leadership transition, with the company boosting shareholder returns through buybacks and dividends.
Outlook remains positive given strong cash flow, declining debt, and analyst consensus favoring the stock. Key risks include commodity price volatility and operational challenges. The investment opportunity centers on SU's integrated model and shareholder returns, though investors should weigh exposure to energy market fluctuations.
TMDX trades at $79.00, down 2.55% amid bearish technical signals. The stock shows strong profitability with 22.69% net margin and 36.28% ROE, though recent earnings misses and margin compression from 2025 to 2026 raise concerns. Analyst consensus remains bullish with a $99.75 price target, but multiple legal investigations into fiduciary duties create uncertainty. Revenue growth continues with 2026 guidance at $668M.
The stock presents a growth opportunity with analyst upside potential, but faces near-term headwinds from earnings volatility and legal scrutiny. Execution on 2026 guidance and resolution of governance concerns will be critical for sustained momentum. Current valuation at 20.47 P/E appears reasonable given growth prospects if operational targets are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Suncor Energy Inc.
Suncor Energy Inc is an integrated energy company. The company's operations include oil sands development, production and upgrading, offshore oil and gas, petroleum refining in Canada and the U.S. and the company's PetroCanada retail and wholesale distribution networks. The company is developing petroleum resources while advancing the transition to a low-emissions future through investment in power, renewable fuels and hydrogen. It also conducts energy trading activities focused principally on the marketing and trading of crude oil, natural gas, byproducts, refined products and power.
Read more on SU →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
